Biotech "Tweets of the Week"
April Fool's Double Feature
(March 21 - April 1, 2016)
Headlines - $ACAD $ALDR $BIIB $BMRN $GILD $IONS $MRK $PTLA $VRX
In the News - $AVEO $BLRX $BLUE $CPXX $CRVS $FOLD $GNCA $MDVN $PBYI $PETX $REGN $SRPT
$XBI $IBB $LABU
Looking for past biotech highlights? Check out the Biotech Tweets of the Week archive.
Adios to the First Quarter $XBI $IBB
$IBB trading above its 50SMA. First time in 3 months.
— BioStockAddict (@BioStockAddict) March 31, 2016
BLAME BIOTECH FOR THIS: S&P 500 health-care stocks drop 5.9% in 1Q, making them the worst-performing sector for the first time in 10 years.
— Steven Russolillo (@srussolillo) March 31, 2016
2 things that shocked me this Q #1 how weak #biotech was I thought it would be a rough year but was not prepared for the 6 week 35% decline
— Dan Rosenblum (@sharkbiotech) March 31, 2016
#2 how strong the snapback from lows would be I dont ANYONE even the most bullish bull thought in mid Feb we would close the Q green
— Dan Rosenblum (@sharkbiotech) March 31, 2016
S&P Sector ETFs (plus Biotech) year-to-date performance (%). Utilities leading, Biotech lagging. $SPY $XLU $XBI pic.twitter.com/s0zbvTnpuj
— Jack Damn (@JackDamn) April 1, 2016
Good riddance: 1Q2016 was 4th worst Q for $NBI since inception in '93. Beaten by 3 Qs during 2001-02 collapse. From @MarkSchoenebaum
— Bruce Booth (@LifeSciVC) April 1, 2016
Biomarin's rare disease data has a few warts $BMRN
$BMRN Phase 3 Study Of Pegvaliase For Phenylketonuria (PKU) Meets Primary Endpoint Of Blood Phenylalanine (PHE) Reduction
— Bio Stocks™ (@BioStocks) March 21, 2016
$BMRN link to the press release: https://t.co/8JHRHIYxEO pic.twitter.com/aFbBBeBJqu
— Brad Loncar (@bradloncar) March 21, 2016
$BMRN - Fair to call pegvaliase study results mixed? PKU levels reduced, as expected, but no neurocog benefit (small + trend.) Any thoughts?
— Adam Feuerstein (@adamfeuerstein) March 21, 2016
peg pal data not what the mkt ordered $BMRN
— zach (@zbiotech) March 21, 2016
piper says pegvaliase data supports 'new leg of growth' for $BMRN - sees 500-600m peak
— zach (@zbiotech) March 21, 2016
The key for a new PKU drug is to keep patients diet free. Only 5% of patients on Kuvan achieve that, how many with pegvaliase? $BMRN
— Juan P. Serrate, DVM (@JPZaragoza1) March 21, 2016
$BMRN are showing us all that winning in rare disease space is no slam dunk
— David Grainger (@sciencescanner) March 21, 2016
$BMRN Post-call, I think regulatory & commercial risk for pegvaliase is higher. Neurcog trend went AGAINST drug. Wasn’t clear from PR.
— Adam Feuerstein (@adamfeuerstein) March 21, 2016
$BMRN @Sport234a The biggest issue is ADHD-RS actually worsened in pts w/ baseline above >9, i.e. potential harm... pic.twitter.com/33f5lTolWU
— Andy Biotech (@AndyBiotech) March 21, 2016
Valeant: fresh accusations as CEO prepares to depart $VRX
barclays finally enters the realm of reality, $VRX to equalweight, $35 tgt
— zach (@zbiotech) March 21, 2016
Valeant Pharma (VRX) opening delayed news pending https://t.co/M9V2Oaop9y via @Street_Insider
— HumbleBioTrader (@HumbleBioTrader) March 21, 2016
$VRX news:
— Meg Tirrell (@megtirrell) March 21, 2016
Pearson out
Ackman joins board
Schiller refuses to resign from board at co's requesthttps://t.co/rHHcP4ztmg
$VRX "The tone at the top of the organization...may have been contributing factors resulting in the company's improper revenue recognition."
— Matthew Herper (@matthewherper) March 21, 2016
Why would you not resign from Valeant when asked? I'd like to resign from Valeant and I don't even work there.
— Matt Levine (@matt_levine) March 21, 2016
If you read the $VRX Sec filing the co is basically calling upon Justice Dept to arrest fmr CFO for fraud. How could Pearson not have known?
— Zachary Prensky (@Zackfoot) March 21, 2016
"What is: Valeant?" $VRX pic.twitter.com/hGhFBqOpXC
— Jeopardy! Stocks (@JeopardyStocks) March 21, 2016
$VRX board member Schiller statement: At no time did I engage in any improper conduct; won't resignhttps://t.co/M6BQ5B0de8 #pharma #biotech
— Donna Young (@ScripDonnaDC) March 21, 2016
$VRX: "We are aware of Mr. Schiller's views, and the company stands by its statement in the company's press release and 8-K."
— Meg Tirrell (@megtirrell) March 21, 2016
One reason Howard Schiller might be sticking around at Valeant -- the board's pay clawback policy $VRX https://t.co/l0n3ImBLYC
— Drew Armstrong (@ArmstrongDrew) March 21, 2016
Tweeps tweeting too much about $VRX. It wasn't the 1st book-cooking drug/biotech co, and it won't be the last.
— Roy Friedman (@DewDiligence) March 21, 2016
Patent issues strike Biogen, Gilead $BIIB $GILD $MRK $IONS
bass IPR for $BIIB tecfidera instituted - patent '514, expires 2028
— zach (@zbiotech) March 22, 2016
$BIIB will be alright. That Alzheimer’s drug has a 90% probability of success!
— Adam Feuerstein (@adamfeuerstein) March 22, 2016
$GILD vs $MRK #HCV patent trial: Jury finds that Merck patents valid and the case proceeds to damages next.
— Andy Biotech (@AndyBiotech) March 22, 2016
@AndyBiotech I still don't like Merck's strategy here. The old Merck would have just won the HCV market with superior R&D
— Stan D'Andrea (@stanleydandrea) March 22, 2016
both $BIIB and $GILD have negative patent news tonight, what are the chances
— Dan Rosenblum (@sharkbiotech) March 22, 2016
Ionis Pharmaceuticals and Merck Receive Positive Verdict on Gilead HCV Drug Patent Case $IONS https://t.co/Oj6bcj3uRz via @YahooFinance
— Biotech 5 (@Biotech_5) March 22, 2016
$gild surprised it's only down 3%. Even a 10% royalty rate should be worth more than that. $mrk $ions
— Dirk Haussecker (@RNAiAnalyst) March 22, 2016
$GILD Barclays spoke to mgt, mgt voiced zero intent to pursue a settlement and clearly believes that it has a better chance in appeal court.
— Andy Biotech (@AndyBiotech) March 23, 2016
$IONS was $47s pre market now $43
— Dan Rosenblum (@sharkbiotech) March 23, 2016
$gild ordered to pay $mrk $200 mln in hepatitis C drug patent dispute-far less than the $2 billion $mrk had demandedhttps://t.co/hlaLxVSexd
— Douglas Allan (@Dougallan1) March 25, 2016
Only Portola is impressed with their phase 3 blood thinner data $PTLA
$PTLA 4AM PR announcing a 8:30AM call "to provide a company update"...
— Andy Biotech (@AndyBiotech) March 24, 2016
$PTLA is a widely loved and followed stock by the pros. This was from a Credit Suisse survey earlier this year. pic.twitter.com/GO1Y1kpmED
— Brad Loncar (@bradloncar) March 24, 2016
$PTLA Betrixaban Ph3 fail to show superiority vs SoChttps://t.co/DafL9nxag0
— Andy Biotech (@AndyBiotech) March 24, 2016
1. missed stats
— zach (@zbiotech) March 24, 2016
2. worse safety
3. marginal mkt need
next... $PTLA
Whats very clear from the APEX top-line results is that betrixaban superiority is the same in all the sub-groups (RR = ~0.80)
— David Grainger (@sciencescanner) March 24, 2016
One person who has been consistently skeptical of $PTLA is @DewDiligence. Another great call by Roy.
— Brad Loncar (@bradloncar) March 24, 2016
Portola Pharma stock drops 30% premarket after trial disappoints $PTLA
— Biotech 5 (@Biotech_5) March 24, 2016
$PTLA ~825m EV here at $21.50 w/assumed cash level post Q1 burn of ~$6.90...seems to imply no risk to ~300M in andexanet sales
— zach (@zbiotech) March 24, 2016
$PTLA says more data at ISTH (June). There's been no additional data on this conference call.
— PropThink (@PropThinker) March 24, 2016
$PTLA trial was 90% powered to demonstrated 35% relative RR with a p-value of <0.01...but hey guys, let's focus on 'just missing' 0.05
— zach (@zbiotech) March 24, 2016
@zbiotech this has always been the issue, but they think medically ill VTE is huge untapped market
— Ethan Weiss (@ethanjweiss) March 24, 2016
Alder provides relief with positive migraine study data $ALDR
$ALDR data out: https://t.co/WQabF1SL5s pic.twitter.com/cBQaD3fi8A
— Brad Loncar (@bradloncar) March 28, 2016
$ALDR This $TEVA Ph2b chronic migraine data will be what folks try to compare to:https://t.co/kaySRsij35
— Andy Biotech (@AndyBiotech) March 28, 2016
$ALDR up 17% pre-market as migraine drug hits main goal in clinical trial: https://t.co/6c5OHuE2Te
— Meg Tirrell (@megtirrell) March 28, 2016
$ALDR will be interesting to see if 24week data has increased separation of doses vs pbo since they are getting dosses every 12 weeks
— Red Acre Investments (@redacre) March 28, 2016
@ohadhammer Think we’d be viewing the result a lot differently if the stock wasn’t already down so much YTD.
— Brad Loncar (@bradloncar) March 28, 2016
i only saw mean change in migraine days for wks 1-4, wks 9-12 analysis more imp given their quarterly regimen $ALDR pic.twitter.com/9tE07xZ0Xw
— zach (@zbiotech) March 28, 2016
Today, the sell-side taught me that everyone has a CGRP migraine drug and each one is benefitting from the $ALDR data.
— Adam Feuerstein (@adamfeuerstein) March 28, 2016
As with anti-depressants a durable placebo effect is as good as the "real thing." Gotta get approved first of course. $ALDR
— NSharma (@Sharma1981N) March 29, 2016
Acadia wins thumbs up for psychiatric drug from FDA panel $ACAD
$ACAD FDA AdCom briefing document outhttps://t.co/lSvgLm8ha4
— Andy Biotech (@AndyBiotech) March 25, 2016
$ACAD briefing docs much more positive than expected, imho. With so much neg. sentiment going in wouldn't be surprised by rally on Monday
— Julia Skripka-Serry (@JuliaSkripkaSer) March 25, 2016
Takeda/Lundbeck Receive CRL for Brintellix sNDA after FDA PDAC 8-2 positive votehttps://t.co/mvutRJMWbR
— Andy Biotech (@AndyBiotech) March 29, 2016
Same panel for $ACAD tomorrow
Most sig takeaway from $ACAD panel may not be act Nuplazid PDP at all. Instead, big safety/regulatory hurdle for next ADP trial.
— Adam Feuerstein (@adamfeuerstein) March 29, 2016
$ACAD Safety Question Vote Result: 11 Yes 3 NO
— Red Acre Investments (@redacre) March 29, 2016
Results Wire: #FDA AdComm Supports Approval of $ACAD Nuplazid (Pimavanserin) for Psychosis with Parkinson’s Disease https://t.co/kh7pvUTY0z
— SAC Tracker (@FDAadcomm) March 29, 2016
Congrats to $ACAD. If I put all my money in this stock at $1.25 back 4 years ago I'd be retired and playing golf everyday!
— Jason Napodano, CFA (@JNapodano) March 29, 2016
$ACAD $29 first trade (from $23.81).
— Brad Loncar (@bradloncar) March 29, 2016
$acad
— S Manian (@DrSManian) March 29, 2016
Short interest 17 Million shares
Big Baker Bro stake 20 Million shares#squeezealert
@PharmDFoose Limit hit to cover $ACAD at 27 today. Left some on the table but happy to catch a piece of the fade.
— Brice Foose (@PharmDFoose) March 31, 2016
As seen on the stream
Anthem sues Express Scripts, seeks to recover damages for pricing & operational issues; $ESRX down 2.5%, $ANTM down 1.5%
— CNBC Now (@CNBCnow) March 21, 2016
Chardan "market underestimating odds Praluent will be removed from US market" Says permanent injuction reasonably likely outcome $REGN $AMGN
— Tyler (@TylerHCanalyst) March 21, 2016
$SRPT supported by 36 researchers and clinicians in letter to FDA #AA #MakeDuchenneHistory https://t.co/FDFetQJNbS
— Christine McSherry (@fundDuchenne) March 21, 2016
$RXDX pop from some insider buying. It’s nice to see how this is becoming a mini-theme lately.
— Brad Loncar (@bradloncar) March 21, 2016
Today's #Biotech Winners$CARA+21%$OVAS+21.05%$SRPT+20.61%$TLOG+19.02%$VCELV+14.75%$ADXS+12.26%$CLDX+11.76%$CPXX+11.61%$GWPH+11.2%
— Biotech 5 (@Biotech_5) March 21, 2016
Reminder: some bio stocks are better to long or short than to tweet about
— Stan D'Andrea (@stanleydandrea) March 21, 2016
$PETX Early FDA approval beats release of @Bioterp 31-page report by hours. Zack's first $1,000,000 position ever. Outperforming IBB et al.
— Steve Newby (@xnBioPartners) March 21, 2016
@carpetscott bears can't win every day. They have been on easy street forever in that name, but doesn't last.
— Adam Singer (@AdamSinger) March 22, 2016
@PropThinker it did today $CEMP.....lol
— Tricia Dineen (@MsTriciaD) March 22, 2016
$CRVS Corvus Pharmaceuticals prices #IPO. 4.7M shares at $15/share.
— Bio Stocks™ (@BioStocks) March 22, 2016
BMS Secures The Keys To Padlock for up to $600M. A great startup story, congrats @michael_gilman and team! https://t.co/uHlcQjK4m9
— Bruce Booth (@LifeSciVC) March 23, 2016
Trillium Therapeutics Insider buying: Director Sievers, Ericr buying 23K $TRIL's shares with value of US $188,994 at an avg price of $8.21
— Joe (@GantosJ) March 23, 2016
Oh look $CRVS #IPO breaking #IPO issue price($15) I am shocked, now $14.75... The new normal, market back towards high, no risk appetite.
— Jean Fonteneau (@JFinDallas) March 23, 2016
@m_denniswinters I appreciate $CPXX breaking F-R Rule b/c it validates the rule. All rules have exceptions, which means F-R Rule is real!
— Adam Feuerstein (@adamfeuerstein) March 23, 2016
Sold some $CPXX plus 603%
— 4th Quarter Capital (@4thQuarterCap) March 23, 2016
$VTAE offering...
— Vikram (@biotechinvstr) March 23, 2016
$LABU - 1:4 reverse split today
— Sudhanva Raj (@SudhanvaRaj) March 24, 2016
$IBB nHod$XON $REGN $KITE $BIIB $CELG$GILD $INCY $AMGN $ALNY $JUNO$VRTX $MDVN $MACK $CARA $BMRN$NKTR $ZIOP $DEPO $FGEN $SGMO
— Tom Wrigley (@WrigleyTom) March 24, 2016
Listening to honorable BioTwitter member @Mykalt45 talk nonsense mutations, DNA, tRNA, mRNA over my head $VRTX $PTCT pic.twitter.com/UaJCo71eLm
— Jean Fonteneau (@JFinDallas) March 24, 2016
Recent buys: $CARA: up 7.37%; $FATE: 7.77%; $CYTK: up 1.9%
— Helen Ong (@Lin_ling_88) March 24, 2016
Amazing #... $BLUE is down 80.1% from the May 2015 All-time high
— Shane Blackmon (@shaneblackmon) March 24, 2016
$APRI..$1.40..Hit high of $1.54 earlier today from $1.09 last week off of the Beaten Bios list. Expecting PH 2 data any day now. Be careful!
— Sheff (@SheffStation) March 24, 2016
$GILD CEO interview by @megtirrell we have to talk about the value &benefit we brings- IT IS A CURE & not treatmenthttps://t.co/JR4BdvkcVw
— Joe (@GantosJ) March 24, 2016
$CYTR: Any biotech that pays an IR firm in stock or warrants is an automatic sell, IMO. @danwardbio
— Roy Friedman (@DewDiligence) March 27, 2016
$ACAD ($24) & $ALDR ($22) having solid pre-mkts!
— Sheff (@SheffStation) March 28, 2016
Biotech has 2nd week of inflows in 2016, according to Raymond James: $144m for week ending March 23
— Meg Tirrell (@megtirrell) March 28, 2016
@bradloncar the clinical trial costs lay the groundwork for justifying future treatment pricing but those numbers will get audited by payers
— David Maizenberg (@biologypartners) March 28, 2016
$PBYI forced to delay neratinib NDA filing until mid-2016 (from Q1.) FDA asked for changes to statistical plan.
— Adam Feuerstein (@adamfeuerstein) March 28, 2016
When a biotech company "updates timeline" for a new drug application, you can assume it's not being expedited.
— Charley Grant (@CGrantWSJ) March 28, 2016
12 congressmen ask NIH, HHS to examine $MDVN's Xtandi pricing. Letter here: https://t.co/kaodTemjvc
— Meg Tirrell (@megtirrell) March 28, 2016
This sector doesn’t exist without IP. Can’t have the gov’t calling that into question.
— Brad Loncar (@bradloncar) March 28, 2016
@stanleydandrea After spending good money on the basic research, the gov would be effectively mothballing the most promising results
— Stan D'Andrea (@stanleydandrea) March 28, 2016
Two of the most important drugs of the last century - Harvoni and Enzalutamide - are regularly and inexplicably excoriated.
— daviesbj (@daviesbj) March 28, 2016
JCI paper on Theranos accuracy woes. Nail meet coffin. https://t.co/bCeJRhxlRN
— Bijan Salehizadeh (@bijans) March 28, 2016
The Theranos story does not seem to want to go away. It is the Kardashians of biotech.
— Ethan Weiss (@ethanjweiss) March 29, 2016
$AUPH Announces Result from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis – Study to Continue as Planned
— ZOZOTRADER (@zozotrader) March 29, 2016
$BLRX With reported CR+CRI rates of only 38, BL-8040 is far from an acceptable standard of care for relapsed disease..Not impressive
— roy vimer (@roiev123) March 29, 2016
$IBB $XBI $MDVN (5/N) Bottomline: think this is just more political noises and NIH is smart enough to not open the Pandora's box.
— Andy Biotech (@AndyBiotech) March 29, 2016
$AVEO & 3 top execs settle fraud charges with SEC related to tivozanib status with FDA —> https://t.co/90DwS1Mbph
— Adam Feuerstein (@adamfeuerstein) March 29, 2016
$ARIA Announces Reduction in Workforce as Part of Ongoing Company-Wide Strategic Review https://t.co/l4RPX3QzmQ via @YahooFinance
— Odi (@odibro) March 29, 2016
an abstract at #AACR16 caught my eye so I wrote it up$KITE $JUNOhttps://t.co/WGsJj0B7BP pic.twitter.com/hSy8xuOYZg
— Paul D. Rennert (@PDRennert) March 29, 2016
$ESPR has had 5 failed breakouts since Jan - 16.43 triggers a 6th attempt. Hard stop 14.69. Will update as it develops.
— BioBounce.com (@BioBounce) March 30, 2016
#Bloomberg, others give $125 million for #immunotherapy #cancer research at Johns Hopkins University https://t.co/FHciaQI4j6
— Ben Hirschler (@reutersBenHir) March 30, 2016
BPC updates: $ACAD +ve Adcom. $OPK CRL. $PTIE $DRRX resub NDA + $AEZS $AMPE $ARLZ $AUPH $BLRX $CBAY $CLBS + more https://t.co/Lyb1xgRirV
— BioPharmCatalyst (@crusadernz) March 30, 2016
Sold 1/2 $KPTI 9.36 for a nice 30% gain from $7.17, will continue to trade this one $KPTI https://t.co/82jxsC4d9o
— BioHunter (@TheBio_Hunter) March 30, 2016
$XBI formed a nice base, maybe we can put in a new swing high soon, higher low etc and back to bioequity world domination.And then i woke up
— Dr. Paul DeSantis (@DrPaulyDeSantis) March 30, 2016
Qtr Cleaning, nLod$IBB $GILD $OPHT $CBPO $BMRN$NLNK $INCY $SAGE $DVAX $VRX$ZIOP $ALXN $AMGN $CELG $CLVS$XON $REGN $ALDR $ALNY $BIIB
— Tom Wrigley (@WrigleyTom) March 30, 2016
Looks like biotech rally was used as an opportunity to get them off the books before quarter end.
— David Sobek (@dsobek) March 30, 2016
All 8 Q1 IPOs were health care raising total $700M - trading up 20%
— Brian Gallagher, Jr. (@bmgallagherjr) March 30, 2016
Renaissance Capital's 1Q16 US IPO Market Review https://t.co/grSqegsDR5
@adamfeuerstein Debt, of course, because it worked out so well for the other toenail fungus company.
— Brad Loncar (@bradloncar) March 30, 2016
$MDVN says no plans to sell itself...to work w/bankers to defend against takeover
— zach (@zbiotech) March 30, 2016
@robertcshea out second half at $41.40. It goes higher but sticking with my plan of just a swing.
— Bobby Shea (@robertcshea) March 30, 2016
@tgtxdough Smid-caps been disproportionately affected – with a 45% reduction in cumulative market value sincemid-2015 high ($292bn to $161bn
— dough (@tgtxdough) March 31, 2016
Hell hath no fury like a biotech scorned
— Todd Harrison (@todd_harrison) March 31, 2016
$LIFE downgraded to Market Perform at William Blair
— Bio Stocks™ (@BioStocks) March 31, 2016
$GNCA is a crowded short for a reason. No need to cover
— DeadCatBill (@getbillasap) March 31, 2016
If IBB can get thru its 50-day, it will be another sector than can help fuel this rally. Tons of short interest in the sector.
— Joseph Fahmy (@jfahmy) March 31, 2016
$FPRX Wow complete 2016 recovery, 43% swing, beautiful, don't panic, #1 position #mrmarket pic.twitter.com/UUCiMcwCQX
— BayAreaBiotechI (@BayAreaBiotechI) March 31, 2016
Big #biotech show tonight with @jimcramer with the CEOs of Radius Health $RDUS & Seres Therapeutics $MCRB H/T @barbara_ryan12
— Amit Jolly (@amitkjolly) March 31, 2016
It's hip to be in biotech again!!$MDVN $ACAD $ INCY $CELG$JUNO $RLYP $SAGE $NBIX $BLCM $SRPT $ADAP
— HumbleBioTrader (@HumbleBioTrader) March 31, 2016
@Liquid_Biopsy $SAGE nice recovery from the short attack last week @KerrisdaleCap thanks for cheap shares
— dough (@tgtxdough) March 31, 2016
"tough quarter eh - what's your strategy here?"
— StockCats (@StockCats) March 31, 2016
"just gonna buy a bunch of beaten-down biotechs and roll the dice"
@missyaubaby @DrSManian no insider buying. all options grants. fwiw.
— Colfax (@ColfaxCapital) March 31, 2016
$BMRN +7% as it bounces off 200d & tries to break out of bear channel - https://t.co/tYOrCuT6dt
— Al Sabogal (@alsabogal) March 31, 2016
@Calculatorci llol thats exactly what it's like
— E B (@Mazmasta) March 31, 2016
@sheffstation Agree Sheff, do you know if Wedbush covers BLUE? They’re very negative on ONCE, wondering if they hate the whole GT sector
— Dan Smithey (@dan_smithey) March 31, 2016
$JAZZ defitelio - ~$160k for 3wk course
— zach (@zbiotech) March 31, 2016
$adms gets market outperform & $29 PT from JMP, who initiated coverage.
— Joe (@Drchik23) April 1, 2016
How's this for a new twist on #biotech? Productizing birth canal bacteria https://t.co/3yumhIT08Z @xconomy @PureTechH
— Steven Dickman (@cbtadvisors) April 1, 2016
EMA CHMP March mtg highlightshttps://t.co/jOGqlb9FTe
— Andy Biotech (@AndyBiotech) April 1, 2016
Positive opinions:$FOLD migalastat$JNJ daratumumab$NVS Entresto$GSK Gene therapy
Regeneron's eczema drug just blew away expectations in a trial: https://t.co/W9BZ9t5sjj by @matthewherper pic.twitter.com/BXfDCNgHx6
— Forbes Health (@forbeshealth) April 1, 2016
There are TONS of biotechs that are down 50% or more and their short interest has doubled. Similar to TSLA, we could see some nice squeezes.
— Joseph Fahmy (@jfahmy) April 1, 2016
Love this...the transformation of $BMY's product offerings. From Windex to Opdivo. pic.twitter.com/iGF1Mjy1pM
— Brad Loncar (@bradloncar) March 31, 2016